SAD Biology and PFAS Disruption Points
Seasonal affective disorder (SAD) is triggered by reduced light exposure in winter months, which impairs melatonin rhythm regulation and reduces serotonin synthesis in the brain. Thyroid hormones also influence seasonal mood — hypothyroidism mimics SAD symptoms and occurs at higher rates in winter when light exposure is reduced. PFAS disrupt both melatonin synthesis (through pineal gland effects) and thyroid hormone availability.
The circadian clock genes (CLOCK, BMAL1, PER) that govern light-responsive daily rhythms are altered by PFAS exposure in animal studies, potentially reducing the precision of circadian entrainment to seasonal light changes. Imprecise circadian entrainment could increase vulnerability to seasonal mood disruption.
Research Evidence
Direct studies of PFAS and SAD are limited, but the overlap between PFAS-affected biological systems and SAD pathophysiology is extensive. Studies of PFAS effects on melatonin secretion — finding altered nocturnal melatonin peaks in PFAS-exposed individuals — are consistent with SAD vulnerability mechanisms.
Communities with PFAS-contaminated water in northern latitudes — where SAD is endemic — provide a natural study setting. Comparative studies of SAD prevalence and severity in contaminated versus clean-water communities controlling for latitude, genetic ancestry, and socioeconomic factors would provide valuable data on this potential interaction.
Clinical and Therapeutic Implications
Psychiatrists and primary care physicians treating SAD in PFAS-contaminated areas may find that standard light therapy and serotonergic antidepressants are less effective when underlying PFAS-mediated thyroid and melatonin disruption are not addressed. Thyroid function testing — including free T3 and T4, not just TSH — is warranted in SAD patients in contaminated communities.
Light therapy — the primary evidence-based SAD treatment — works through serotonin and melatonin pathways that PFAS disrupt, and may need to be more intensive or prolonged for PFAS-exposed patients to achieve equivalent benefits. Addressing both the seasonal trigger and the PFAS-mediated biological vulnerability through exposure reduction provides the most comprehensive management approach.